PE
SGMT icon

Point72 Europe’s Sagimet Biosciences SGMT Stock Holding History

Point72 Europe’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$357 Buy
+52
New +$422 ﹤0.01% 714

Other funds holding SGMT

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Point72 Europe's SGMT Position: Q3 2025 in Review

Point72 Europe opened a new position in Sagimet Biosciences (SGMT) in Q3 2025: 52 shares worth $357. The stake represents ﹤0.01% of the portfolio and ranks #714 among its holdings.

72 funds tracked by Wall St. Rank hold SGMT as of Q3 2025.

  • Point72 Europe held 52 shares of Sagimet Biosciences worth $357 as of Q3 2025.
  • Sagimet Biosciences was a new Point72 Europe position in Q3 2025.
  • Sagimet Biosciences made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #714 holding.
  • 72 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.